Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer

Solid Neoplasm Clinical Trial

Official title:

Advancing Screening and Treatment for Older Patients With Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02517034
• Other study ID #: 15161
• Secondary ID: NCI-2015-0120215
• Status: Active, not recruiting
• Phase: N/A
• Start date: August 4, 2015
• Est. completion date: June 20, 2024

Study information

• Verified date: December 2023
• Source: City of Hope Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized clinical trial studies a geriatric assessment intervention in predicting chemotherapy toxicity and vulnerabilities (or weakness) in older patients with cancer. Assessing patients' functional status, comorbidities, psychological state, social support, nutritional status, and cognitive function before treatment may help identify vulnerabilities, improve care, and decrease chemotherapy side effects in older patients with cancer.

Description:

PRIMARY OBJECTIVES: I. To identify areas of vulnerability in older adults with cancer through the use of a geriatric assessment, and to identify the potential referrals to an interdisciplinary team based on geriatric assessment results. II. To determine whether the geriatric assessment driven interventions will lead to decrease in grade 3-5 toxicity. SECONDARY OBJECTIVES: I. To determine whether the geriatric assessment driven interventions will lead to improvement in the following outcomes: unplanned hospitalization, average length of stay (ALOS), emergency visits, unplanned readmission rates, and advance directive completion. II. To determine whether there is significantly better quality of life (QOL) and function in the geriatric assessment intervention group compared to the standard of care group from start of treatment to the follow-up timepoint. III. To determine the feasibility of delivering geriatric assessment driven interventions in a community setting using telemedicine. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients follow an intervention plan created by the nurse practitioner (NP) using the results of the geriatric assessment. The NP discusses the results of the assessment and treatment recommendations with the patient. They also share the treatment plan, proposed referrals, and specific vulnerabilities with the primary care physician and community oncologist. Some patients complete the intervention plan via Telehealth, which uses telecommunication technology to provide health services over a distance. ARM II: Patients follow a standard of care treatment plan at the discretion of the primary oncologist. Beginning 6 months from the start of chemotherapy, patients undergo the geriatric assessment as in Arm I. Some patients complete the standard of care treatment plan via Telehealth.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 600
• Est. completion date: June 20, 2024
• Est. primary completion date: June 20, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of a solid tumor malignancy (any stage)
• Scheduled to start a new chemotherapy regimen (any line, combination cytotoxic chemotherapy with targeted agents are allowed)
• English, Spanish, and/or Chinese speaking
• Able to provide written informed consent

Exclusion Criteria:

• Not fluent in English, Spanish and/or Chinese (because not all questionnaires have been validated in other languages)

Related Conditions & MeSH terms

• Solid Neoplasm

Intervention

Other:
• Comprehensive Geriatric Assessment
Follow geriatric assessment-driven treatment plan
• Quality-of-Life Assessment
Ancillary studies
• Questionnaire Administration
Ancillary studies
• Survey Administration
Ancillary studies

Locations

Country	Name	City	State
United States	City of Hope Medical Center	Duarte	California
United States	City of Hope Antelope Valley	Lancaster	California
United States	City of Hope Rancho Cucamonga	Rancho Cucamonga	California
United States	City of Hope South Pasadena	South Pasadena	California
United States	City of Hope West Covina	West Covina	California

Sponsors (2)

Lead Sponsor	Collaborator
City of Hope Medical Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of grade 3-5 toxicity during chemotherapy	Compared pre versus (vs) post-chemotherapy. Tested using general linear models with an alpha of 0.05.	Up to 6 months
Secondary	Rate of hospitalizations during chemotherapy	Compared pre vs post-chemotherapy. General linear models will be considered for testing, but no alpha adjustments will be applied for multiple comparisons.	Up to 6 months
Secondary	Change in functional status as measured by the Older American Resources and Services Instrumental Activities of Daily Living	Compared pre vs post-chemotherapy. Explored using multivariate analyses. Results will be stratified by covariates such as patient age, poly- versus mono-chemotherapy, dose reduced or full dose therapy upfront, adjuvant versus metastatic disease, and number of prior chemotherapy regimens.	Baseline to up to 6 months
Secondary	Change in quality of life as measured by Functional Assessment of Cancer Therapy - General	Compared pre vs post-chemotherapy. Explored using multivariate analyses. Results will be stratified by covariates such as patient age, poly- versus mono-chemotherapy, dose reduced or full dose therapy upfront, adjuvant versus metastatic disease, and number of prior chemotherapy regimens.	Baseline to up to 6 months